Background: MicroRNAs (miRNAs) have become increasingly prevalent as a result
Alzheimer's disease (AD), with a high prevalence of 11 million people worldwide, is recognized as the most common form of dementia. As a progressive neurodegenerative disorder, this disease results in a debilitating decline of different dimensions of cognitive performance, deterioration in language, social isolation, and a gradually decreased self-sufficiency. These symptoms cause a large reduction in the lifeexpectancy of AD patients, whereas the mortality rate caused by AD increased to 71% between 2000 and 2013. 1 Therefore, there is an urgent need to improve our understanding of the risk factors and pathophysiological mechanisms with respect to AD and thus the development of an early biomarker detection methodology, as well as proper therapeutic treatments, for AD patients.
MicroRNAs (miRNAs) is a group of small noncoding RNA molecules that can interfere with the epigenetic regulation of gene expression, translation of target mRNAs and protein production. 2 The involvement of miRNAs in AD progression has been studied extensively in the past decades because the deregulation of miRNA has been shown to be associated with altered transcription, protein processing, and the stability of the nuclease involved in neurodegenerative disorders. [2] [3] [4] Although numerous studies have been published about miRNA profiling in relation to AD, the roles of miRNAs remain poorly understood. This is largely because of disparate data as a result of differences in technological platforms, sample sizes and data-analysis methods, as well as inconsistent evidence. 5 In the present study, we conducted a systematic bioinformatics analysis aiming to provide valid evidence on AD relating to miRNAs and their target genes with increased statistical power as a result of using the publicized data available in the GEO database (https:// www.ncbi.nlm.nih.gov/geo/). In addition, we investigated the functions of dysregulated miRNA target genes in the pathological process of AD. Furthermore, our study emphasizes the potential value of target genes in the prevention and treatment of AD as a result of using miRNAs.
| MATERIALS AND METHODS

| Datasets and determination of differentially expressed miRNA profiles
The miRNA expression profiling of AD was selected through Google Scholar (https://scholar.google.com) using the key words 'Alzheimer's Disease' and 'miRNA'. The full text of the publication with respect to each study was assessed thoroughly. Studies were excluded when one of the following criteria was fulfilled: the study investigated individual preselected candidate genes, the study was performed with only cell lines, or the study was conducted without a non-AD sample as the control group.
Information on miRNAs with significantly changed expression levels was derived from the publications. The miRNAs were categorized into up-regulated and down-regulated miRNAs in AD patients compared to healthy controls. The profiles and distributions of up-regulated and down-regulated miRNAs were compared between datasets. Differentially expressed signature miRNAs, which were identified in at least two datasets, were chosen for further analysis.
| miRNA target prediction
Sequences of selected signature miRNAs were standardized according to miRBase, version 21, 6, 7 and stored as a Fasta dataset. Viral nonmiRNAs and miRNAs probes were excluded from the analysis. The putative targets of selected miRNAs were predicted using TargetScan. 8, 9 For the number of each miRNA with significant expression variation, the maximum was set as 200; other analysis parameters were set as default.
| Enrichment analysis
Enrichment analysis for Gene Ontology (GO) terms 10 
| Transcription factor (TF) analysis
TF regulation was predicted by uploading key up-regulated and downregulated miRNAs to TFactS (http://www.tfacts.org/). We considered a TF as regulated, activated or inhibited, respectively, providing that the indicated p-value, q-value, E-value and FDR were all statistically significant (< 0.05). 13 TFs were listed and compared according to the regulation type ('up' or 'down') based on the categorized key miRNAs and then the overlapped TFs were further identified.
| RESULTS
To identify the key miRNAs and to investigate functions of their target genes in pathogenesis of AD, we conducted this systematic analysis following the analysis process shown in Figure 1 . Bioinformatics analysis was applied to select the key significantly up-regulated and down-regulated miRNAs from the nine currently available AD miRNA datasets (Lta, 14 
| Datasets and determination of differentially expressed miRNA profiles
According to the search criteria, nine separate miRNA expression profiling datasets related to AD of nine published studies were retrieved from public databases. Acronyms and characteristics, such as the number of patients and the number of miRNA probes, were used when ranging the datasets. The selected studies are listed in Table 1 . Considerable heterogeneity of sample selection, sample size, and the types of assay was observed in these studies. Distributions of differentially expressed miRNAs of each dataset were reflected using scalable vector graphics ( Figure 2 ).
The number of significantly dysregulated miRNAs varied greatly across the datasets ( Figure 3A ). Only two datasets reported more than 10 significantly differentially expressed miRNAs: datasetLC (17 dysregulated miRNAs) and datasetLTa (13 dysregulated miRNAs). Six datasets identified significantly up-regulated miRNAs. LC reported the largest number of up-regulated miRNAs (14 up-regulated miRNAs), followed by HM (eight up-regulated miRNAs) ( Figure 3B ), whereas DG, PK, and MS did not report any up-regulated miRNA.
Seven datasets identified significantly down-regulated miRNAs, LTa reported the largest number of up-regulated miRNAs (nine downregulated miRNAs), followed by PK (seven down-regulated miRNAs), whereas PN and HM did not report any up-regulated miRNAs. between the profiling datasets showed that a comprehensive systematic analysis was necessary.
| AD miRNA signature
Statistically, we detected 13 significant differentially expressed miRNAs in at least two datasets, which may be considered as key miRNAs in the pathological progress of AD. Compared to non-AD samples, four significantly up-regulated miRNAs were identified in AD samples: hsa-miR-101, hsa-miR-155, hsa-miR-34a and hsa-miR-9.
Nine significantly down-regulated miRNAs were identified: hsa-let7d-5p, hsa-let-7 g-5p, hsa-miR-15b, has-miR-191-5p, hsa-miR-125b, has-miR-26b-5p, hsa-miR-29a, hsa-miR-29b and hsa-miR-3.
Information on chromosomal locations of signature miRNAs genes was derived based on the miRBase ( Table 2 ). The signature miRNAs showed a scattered distribution on the chromosome. Briefly, three signature miRNAs were identified on chromosomes 1 and 3, respectively, and two signature miRNAs were on chromosomes 7 and 21.
In addition, chromosomes 2, 9 and 14 each contained one signature miRNA.
| Target prediction of signature miRNAs
We used an up-to-date prediction algorithm (TargetScan) to predict the target genes of all signature miRNAs. To increase the accuracy of prediction, we limited the maximum number to 200. Except for hsa-miR-191 which had 65 targets genes, other miRNAs all had 200 target genes. 
| The biological functions of signature miRNAs
Enrichment analyses were performed using the predicted target genes to clarify the biological functions of signature miRNAs. Significant heterogeneity was observed in enriched GO processes across 13
signature miRNAs. Figure 4A shows that GO process 'GO:
0006366~transcription from RNA polymerase II promoter' was enriched for up-regulated miRNAs, hsa-miR-155 and hsa-miR-9. Up-regulated miRNAs, hsa-miR-101 and hsa-miR-34a, showed significant enrichment in GO process 'GO: 0007268~chemical synaptic transmissions'.
Five down-regulated miRNAs demonstrated a significant enrichment in the GO process 'GO: 0045944~positive regulation of transcription from RNA polymerase II promoter' .
The results of the KEGG pathway analysis are presented in Figure 4B . Various significant enriched terms of nine miRNA targets datasets were observed. Specifically, only two up-regulated miRNA targets were associated with differentially enriched KEGG pathways.
Three down-regulated miRNA targets were enriched in two pathways 'has04115:p53signaling pathway' and 'hsa05206: MicroRNAs in cancer' , indicating that these two pathways played important roles in the progress of AD.
| TF analysis
We further investigated the TFs regulated by the 13 signature miRNAs, and compared the differences of the TFs between up-regulated and down-regulated miRNAs. Figure 5A shows that 90 TFs were 
| DISCUSSION
In the present study, a total of 13 key miRNAs were identified from nine selected miRNA profiling datasets, including four significantly up-regulated miRNAs and nine significant down-regulated miRNAs.
Among the four up-regulated miRNAs, hsa-miR-9 and hsa-miR-34a
were up-regulated in AD patients in accordance with a recent systematic review. 23 The up-regulated feature of hsa-miR-34a was observed in human studies and then confirmed by animal experiments on mice. 5 Together with reduced anti-apoptotic proteins, a significant reduction of hsa-miR-34a was observed in the human brain of AD patients. 5 The coherent up-regulated function of hsa-miR-155 was also suggested by the latest studies. For example, hsa-miR-155 was shown to be related to the suppression of translation of complement factor H, an important negative regulator of the immune-inflammatory response that is less abundant in AD patients. The results suggested that hsa-miR155plays an important role in the development of AD. 24, 25 By contrast, current evidence does not consistently support the role of hsa-miR-9 in circulation and brain. 22, 26, 27 Additionally, the result with respect to the up-regulated hsa-miR-101 was in conflict with the findings of previous studies, which suggested that down-regulation of hsamiR-101 was a result of elevated pro-inflammatory cyclo-oxygenase-2 in the brain of AD. 28 However, any disagreements between our observations and the existing evidence for hsa-miR-9 and hsa-miRNA101 could be explained by the limitations of the present study. First, we analyzed data from databases generated by different techniques. This could limit any comparisons and the ability to generalize the observed results to others. Accordingly, the need remains to conduct a more comprehensive analysis with more strict inclusion criteria before any conclusion can be reached. Second, the oldest dataset detecting miRNAs dated from 2007 and used a microarray. Given that the microarray is highly restricted to the time of performance, some AD related miRNAs might have been neglected.
As is generally known, the occurrence of AD is largely a result of the progressive dysfunction and death of nerve cells, which play a critical role in the storage and processing of information. Among the nine down-regulated miRNAs, there was abundant evidence to support hsa-miR-125b and hsa-miR-342-3p having reliable decreases across the circulation and brain, [14] [15] [16] 22 which was largely the result of a decrease in nerve cells. The function of the down-regulated miRNAs, hsa-miR15b, hsa-miR-26b-5p and hsa-miR-29a has been summarized in a systematic review. 5 For example, the down-regulation of hsamiR-26b-5p was reflected by its target enzyme: tumor necrosis factor α converting enzyme. This enzyme is associated with α-secretase activity that affects the non-amyloid genic pathway of AD. 5 hsamiR-29a was identified at the pro-survival peptide insulin-like growth factor-1, which influenced Tau production by inhabiting GSK-3 indirectly via phosphoinostide-3 kinase-Akt. 29 The association between the down-regulated miRNAs, as found in the present study, and the speculative and needs more in depth research. In addition, we identified that hsa-let-7d-5p, hsa-let-7 g-5p and hsa-miR-191-5p were down-regulated miRNAs. These three miRNAs are unique circulating miRNA signatures for distinguishing patients with AD from those in the control group, with the more specific mechanism possibly being related to the disturbance of multiple enzymatic pathways. Apart from the 13 critical identified miRNAs, all of the differentially expressed miRNAs identified in the present study were also found to be associated with other diseases, such as cancer and systematic diseases. [30] [31] [32] In summary, the present study indicated that the 13 signature miRNAs could function as key regulatory factors in AD. This is based on gene enrichment analysis, which showed that one single miRNA might affect the expression of multiple target genes, whereas multiple miRNAs could regulate the same mRNA. In the enrichment analysis, we observed enriched GO processes related to the transcription of RNA polymerase II promoter for both up-and down-regulated miRNA targets. The importance of transcription regulation of RNA in the neurological disorders, including AD, has been summarized in a previous study. 33 For example, mediator coactivator can integrate information from transcriptional activators, repressors, and signaling pathways, and it could be mutated through dysregulation of transcription. 33, 34 This revealed that the identified up-and down-regulated miRNAs functioned differentially in AD. Furthermore, two up-regulated miRNAs targets were enriched in one GO process with respect to chemical synaptic transmission. This enriched GO process is a neuromuscular synaptic transmission relationship, as well as a neuron-neuron synaptic transmission relationship, which is important in AD progression. 35 Hence, these two up-regulated miRNAs could disturb the neuron-neuron transmission relationship and interfere with the transportation of neuro signals. Thus, a poor prognosis of AD could be linked to a high level of these two up-regulated miRNAs.
To further understand the role of these key miRNAs in the pathological process of AD, we also performed KEGG pathway analysis.
Considering that all of the identified miRNAs were related to an oncogenic progress, it is not unreasonable that the enriched pathways hsa04115:p53 signaling pathway and hsa05206: MicroRNAs in cancer were observed in the present study. One possible explanation for this is that the important molecular mechanisms involved in oncogenic progress could also contribute to the pathology in AD. For example, pathways of inflammation and oxidation, as well as pathways of innate immunity, were found in studies of both cancer and AD. 30 Although intensively investigated, no systematic conclusion has been reached for the role of miRNAs in these pathways. 5 Thus, given the complexity of both enriched pathways, further study on the role of identified miRNAs in this pathway is warranted.
In conclusion, the present systematic analysis has identified and confirmed 13 key miRNAs associated with AD. The predicted target genes and the biological functions of these key miRNAs provide further insight into the role or functions of miRNAs as therapeutic targets for AD.
